drugset / Trial / NCT00380068

Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension

NCT00380068

Phase 3 Completed 224 enrolled Gilead Sciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study was to evaluate the safety and efficacy of ambrisentan in a broad population of participants with pulmonary hypertension (PH). Secondary objectives of this study were to evaluate the effects of ambrisentan on other clinical measures of pulmonary arterial hypertension (PAH), long-term treatment success, and survival.

Timeline

Start
2006-08
Primary completion
2008-07
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambrisentan Small molecule Oral